NasdaqGM:XNCRBiotechs
A Look At Xencor (XNCR) Valuation After New XmAb819 Renal Cancer Data And Pipeline Milestone Update
Xencor (XNCR) recently outlined 2026 priorities for its XmAb platform, highlighting early clinical data for renal cell carcinoma candidate XmAb819 and setting out timelines for multiple oncology and autoimmune milestones that could influence investor expectations.
See our latest analysis for Xencor.
Despite the fresh 2026 pipeline update, Xencor’s recent share price momentum has been weak, with a 30 day share price return of a 19.05% decline and a 1 year total shareholder return of a 33.52%...